Besonprodil

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524408

CAS#: 253450-09-8

Description: Besonprodil is a drug which acts as an NMDA antagonist, selective for the NR2B subunit. It is under development as a supplemental medication for Parkinson's disease, and has been shown in animals to be effective in counteracting the dyskinesias associated with long term treatment with levodopa and related drugs.


Price and Availability

Size
Price

Size
Price

Size
Price

Besonprodil, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 524408
Name: Besonprodil
CAS#: 253450-09-8
Chemical Formula: C21H23FN2O3S
Exact Mass: 402.14134
Molecular Weight: 402.48
Elemental Analysis: C, 62.67; H, 5.76; F, 4.72; N, 6.96; O, 11.93; S, 7.97


Synonym: Besonprodil; CI-1041; 253450-09-8; UNII-5K3N2D15WW; CHEMBL219631; Besonprodil (USAN); CI1041; PD 196860 ;PD196860;

IUPAC/Chemical Name: (S)-6-((2-(4-(4-fluorobenzyl)piperidin-1-yl)ethyl)sulfinyl)benzo[d]oxazol-2(3H)-one

InChi Key: FCBQJNCAKZSIAH-NDEPHWFRSA-N

InChi Code: InChI=1S/C21H23FN2O3S/c22-17-3-1-15(2-4-17)13-16-7-9-24(10-8-16)11-12-28(26)18-5-6-19-20(14-18)27-21(25)23-19/h1-6,14,16H,7-13H2,(H,23,25)/t28-/m0/s1

SMILES Code: o1c([nH]c2c1cc(cc2)[S@@](=O)CCN1CCC(CC1)Cc1ccc(cc1)F)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Ouattara B, Hoyer D, Grégoire L, Morissette M, Gasparini F, Gomez-Mancilla B, Di Paolo T. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias. Neuroscience. 2010 Jun 2;167(4):1160-7. doi: 10.1016/j.neuroscience.2010.03.022. Epub 2010 Mar 18. PubMed PMID: 20303391.

2: Morissette M, Samadi P, Hadj Tahar A, Bélanger N, Di Paolo T. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 16;34(3):446-54. doi: 10.1016/j.pnpbp.2009.12.011. Epub 2009 Dec 16. PubMed PMID: 20026151.

3: Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides. Neuropharmacology. 2010 Jan;58(1):286-96. doi: 10.1016/j.neuropharm.2009.06.030. Epub 2009 Jul 2. PubMed PMID: 19576910.

4: Ouattara B, Belkhir S, Morissette M, Dridi M, Samadi P, Grégoire L, Meltzer LT, Di Paolo T. Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias. J Mol Neurosci. 2009 Jun;38(2):128-42. doi: 10.1007/s12031-008-9137-8. Epub 2008 Aug 14. PubMed PMID: 18704766.

5: Samadi P, Morissette M, Calon F, Hadj Tahar A, Dridi M, Belanger N, Meltzer LT, Bédard PJ, Di Paolo T. Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys. Synapse. 2008 Feb;62(2):101-9. PubMed PMID: 17992687.

6: Borza I, Bozó E, Barta-Szalai G, Kiss C, Tárkányi G, Demeter A, Gáti T, Háda V, Kolok S, Gere A, Fodor L, Nagy J, Galgóczy K, Magdó I, Agai B, Fetter J, Bertha F, Keserü GM, Horváth C, Farkas S, Greiner I, Domány G. Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides. J Med Chem. 2007 Mar 8;50(5):901-14. Epub 2007 Feb 10. PubMed PMID: 17290978.

7: Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Synapse. 2006 Sep 1;60(3):239-50. PubMed PMID: 16739115.

8: Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov Disord. 2006 Jan;21(1):9-17. PubMed PMID: 16127720.

9: Barton ME, White HS, Wilcox KS. The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on NMDA receptor-mediated EPSCs. Epilepsy Res. 2004 Mar;59(1):13-24. PubMed PMID: 15135163.

10: Barton ME, White HS. The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on kindling acquisition and expression. Epilepsy Res. 2004 Mar;59(1):1-12. PubMed PMID: 15135162.

11: Hadj Tahar A, Grégoire L, Darré A, Bélanger N, Meltzer L, Bédard PJ. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol Dis. 2004 Mar;15(2):171-6. PubMed PMID: 15006686.

12: Kovács G, Kocsis P, Tarnawa I, Horváth C, Szombathelyi Z, Farkas S. NR2B containing NMDA receptor dependent windup of single spinal neurons. Neuropharmacology. 2004 Jan;46(1):23-30. PubMed PMID: 14654094.

13: Chen LR, Wesley JA, Bhattachar S, Ruiz B, Bahash K, Babu SR. Dissolution behavior of a poorly water soluble compound in the presence of Tween 80. Pharm Res. 2003 May;20(5):797-801. PubMed PMID: 12751636.